274 related articles for article (PubMed ID: 17273752)
1. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.
Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Shriver CD; Ponniah S; Peoples GE
Oncol Rep; 2007 Mar; 17(3):687-94. PubMed ID: 17273752
[TBL] [Abstract][Full Text] [Related]
2. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
[TBL] [Abstract][Full Text] [Related]
3. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
[TBL] [Abstract][Full Text] [Related]
4. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
[TBL] [Abstract][Full Text] [Related]
5. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Kao TC; Shriver CD; Ponniah S; Peoples GE
Clin Cancer Res; 2006 Jan; 12(2):478-86. PubMed ID: 16428490
[TBL] [Abstract][Full Text] [Related]
6. Multiplex determination of murine seminal fluid cytokine profiles.
Gopichandran N; Ekbote UV; Walker JJ; Brooke D; Orsi NM
Reproduction; 2006 Mar; 131(3):613-21. PubMed ID: 16514204
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
8. Uterine and serum cytokine arrays in the mouse during estrus.
Orsi NM; Ekbote UV; Walker JJ; Gopichandran N
Anim Reprod Sci; 2007 Aug; 100(3-4):301-10. PubMed ID: 16963201
[TBL] [Abstract][Full Text] [Related]
9. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation.
Stabler T; Piette JC; Chevalier X; Marini-Portugal A; Kraus VB
Arthritis Rheum; 2004 Nov; 50(11):3663-7. PubMed ID: 15529362
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
[TBL] [Abstract][Full Text] [Related]
12. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
13. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
Mittendorf EA; Gurney JM; Storrer CE; Shriver CD; Ponniah S; Peoples GE
Surgery; 2006 Mar; 139(3):407-18. PubMed ID: 16546506
[TBL] [Abstract][Full Text] [Related]
15. Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.
Makimura C; Arao T; Matsuoka H; Takeda M; Kiyota H; Tsurutani J; Fujita Y; Matsumoto K; Kimura H; Otsuka M; Koyama A; Imamura CK; Yamanaka T; Tanaka K; Nishio K; Nakagawa K
Anticancer Res; 2011 Dec; 31(12):4561-8. PubMed ID: 22199331
[TBL] [Abstract][Full Text] [Related]
16. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination.
Burgdorf SK; Claesson MH; Nielsen HJ; Rosenberg J
Acta Oncol; 2009; 48(8):1157-64. PubMed ID: 19863224
[TBL] [Abstract][Full Text] [Related]
17. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
18. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck.
Hoffmann TK; Sonkoly E; Homey B; Scheckenbach K; Gwosdz C; Bas M; Chaker A; Schirlau K; Whiteside TL
Head Neck; 2007 May; 29(5):472-8. PubMed ID: 17111427
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis.
Ishizu T; Osoegawa M; Mei FJ; Kikuchi H; Tanaka M; Takakura Y; Minohara M; Murai H; Mihara F; Taniwaki T; Kira J
Brain; 2005 May; 128(Pt 5):988-1002. PubMed ID: 15743872
[TBL] [Abstract][Full Text] [Related]
20. Differences in amniotic fluid and maternal serum cytokine levels in early midtrimester women without evidence of infection.
Chow SS; Craig ME; Jones CA; Hall B; Catteau J; Lloyd AR; Rawlinson WD
Cytokine; 2008 Oct; 44(1):78-84. PubMed ID: 18703348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
